Shanghai Xuhui Central Hospital
Shanghai, Shanghai Municipality, 200031, China
NCT Number: NCT04779892
A phase 1, Randomized, Double-blind, Parallel group, Sing-dose study to compare the Pharmacokinetics and Safety of CMAB008 and Remicade in healthy subjects.
Looking for future studies?
Notify Me18 year–45 year
Male
Interventional
Phase 1
Shanghai, Shanghai Municipality, 200031, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
100mg/vial
Time frame: up to 1680 hours
Time frame: up to 1680 hours
Time frame: up to 1680 hours
Time frame: up to 1680 hours
Time frame: up to 1680 hours
Time frame: up to 1680 hours
Taizhou Mabtech Pharmaceutical Co.,Ltd
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03649178
Arthritis, Arthritis, Rheumatoid
Nashville, Tennessee, United States
View Trial DetailsNCT03025308
Arthritis, Arthritis, Rheumatoid
Huntsville, Alabama, United States
View Trial DetailsNCT07715045
Arthritis, Arthritis, Rheumatoid
Palembang, South Sumatera, Indonesia
View Trial DetailsNCT00055055
Arthritis, Arthritis, Rheumatoid
Bethesda, Maryland, United States
View Trial Details